Role of the funding source
This systematic review was commissioned and funded by the World Health Organization [HQ/EMP/2019/002, 2019] under a grant from the United Kingdom Department for International Development (DFID). The review was part of the process for developing the 2020 WHO Guideline on Country Pharmaceutical Pricing Policies. The WHO secretariat and its advisors provided technical support for formulating the review protocol, performing specific searches on government websites, and translating several non-English publications. WHO, its advisors and DFID had no role in data analysis or interpretation. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the WHO or DFID.Flow chart of study selection.The number of articles identified through database searching and screening by title and abstract shown in grey apply to the overall search; as per protocol the database search included search terms for all ten specific pricing policies among which policies promoting price transparency was one. The lower part of the flow chart shown in white is specific to the selection of studies on policies promoting price transparency. WoS=Web of Science.*Two articles are part of the same study, but were published separately. These references are considered 